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Abstract. Several investigators have reported retention 
of in d iu m - i l l  in infectious foci after intravenous 
injection of 11 'In-labelled immunoglobulin G (IgG). 
With this study we intended to test the hypothesis that, 
upon administration of 11'In-diethylene triamine penta- 
acetic acid (DTPA-IgG), 11'In is retained in the 
infectious foci after dissociation from IgG. Therefore we 
measured the tissue distribution of double-labelled ' " I n -  
DTPA-IgG-(carbon-14) in rats with a focal infection and 
compared the results with corresponding data for DTPA- 
IgG -( '4C). DTPA-conjugated IgG was labelled with " ' I n  
via citrate transchelation. " 'In-DTPA-IgG and DTPA- 
IgG were labelled with ,4C through methylation. High- 
performance liquid chromatography (HPLC) and instant 
thin-layer chromatography analysis were performed to 
test the in vitro stability of the labelled proteins. Young 
Wistar rats with a Staphylococcus aureus infection of the 
left calf muscle were injected intravenously with 0.2 ml 
of a solution containing either 0.4 MBq ' 1 'In and 30 kBq 
14C or 30 kBq 14C labelled to 80 jig IgG. Groups of five 
rats were sacrificed at 2, 6, 24, and 48 h. p.i. Activity up­
take was determined for plasma, urine, abscess, muscle 
and various other tissues. Averages and standard devia­
tions were calculated for groups of  five rats. HPLC anal­
ysis was performed on plasma and urine samples taken 
up to 48 h p.i. The radiochemical purity of the IgG prep­
arations was >95%. The labelled preparations appeared 
stable in vitro. The 14C abscess activity decreased from 
1.2% to 0.7% of the injected dose per gram (% I.D./g) 
between 2 and 48 h after injection and was linearly relat­
ed to the 14C plasma concentration. However, the " ' I n  
concentration in the infectious foci remained constant
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over time (1.0% I.D./g) despite a decreasing concentra­
tion of " ' I n  in plasma. Labelling with l4C did not influ­
ence the abscess uptake of " ' I n  after administration of 
" 'In-DTPA -IgG. On the other hand, conjugation with 
DTPA and labelling with Ini 1 1 did not influence the tis­
sue distribution of 14C-IgG either. Assuming that 14C- 
IgG behaves like native IgG, our results strongly suggest 
that in abscesses " ' I n  is released from IgG with local re­
tention of the ' " I n .  The dissociation of " ' I n  from IgG 
provides a new explanation for retention of " ' I n  in sites 
of inflammation. This phenomenon might also be rele­
vant to the explanation of non-specific tumour uptake of 
monoclonal antibodies labelled with " ' I n  through 
DTPA.
Key words: Ind ium -111 -  Immunoglobulin G -  Inflam­
mation -  Infection -  Mechanism
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Introduction
Despite the extensive evidence of its clinical usefulness, 
the mechanism of  uptake of " 'In - labe lled  non-specific 
polyclonal human immunoglobulin G (IgG) in foci of in­
flammation and infection remains to be clarified. Several 
mechanisms have been proposed for the uptake of " ' In -  
IgG in inflammatory and infectious foci. At the time of 
its introduction it was postulated that " ' In - Ig G  might 
bind to leucocyte surface receptors through its Fc frag­
ment after exudation through the leaking capillary walls 
at the site of inflammation into the locally expanded ex- 
travascular space [1]. However, the first part of  this hy­
pothesis had to be abandoned for several reasons. First, 
in an autoradiographic study the " ' I n  in the interstitial
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space at the site o f  an infection appeared not to be in­
flammatory cell associated [2]. Second, in infectious fo­
ci 11'In human serum albumin (HSA) performed very 
similarly to ' " In - Ig G  [3]. Third, the uptake of n i In-IgG 
in infections in neutropenic humans and rats was at least 
as high as in otherwise comparable cases with normal or 
elevated leucocyte counts [4].
Binding to Staphylococcus aureus protein A [5], 
monocytes [6] and rheumatoid factors [5] have been pro­
posed to explain retention of  radiolabelled IgG in in­
flammatory foci. However, none of these mechanisms 
provides an adequate explanation for the observed up- 
ake and retention of " ' In - Ig G  in sites of acute and 
Tironic infections by a variety of micro-organisms as 
well as in sterile inflammatory foci [7].
In a pilot study using mixtures of " ' In - Ig G  and car­
bon-14-IgG in rats with a focal S. aureus infection we 
were able to demonstrate that the concentration of 14C- 
IgG in a site of infection is linearly related to the plasma 
concentration, whereas " ' In - Ig G  is retained in an infec- 
ion independent of the plasma concentration [8]. It is 
he objective of this study to provide additional evidence 
f release of indium from indium-labelled IgG by using 




iclium-J 11-IgG. Diethylene triamine penta-acetic acid bicyclic 
ihydride (DTPA bicyclic anhydride, Sigma, St. Louis, Mo.) was 
>njugated to IgG (Sandoglobulin, Sandoz, AG, Nuernberg, Ger- 
lany) according to the technique described by Hnatowich et al. 
>|. The number of DTPA ligands conjugated to one protein mole- 
ile was determined by the method described in the same paper 
>|. The DTPA-conjugated protein, purified by gel filtration on 
ephadex G-25 (Pharmacia LKB, Uppsala, Sweden), was diluted 
) 2 mg/ml with 0.15 M  acetate (pH = 6.5) and sterilized by mem- 
rane filtration (Millipore SA, Molsheim France, Millex-GV 
LGV025LS, 0.22 |im). Aliquots of 1 ml of the conjugate (2 mg 
G) were mixed with 0.1 ml 0.15 M  citrate buffer (pH = 5) and ra- 
olabelled with 10 MBq of 111 In-indium chloride in 0.04 M  hydro- 
iloric acid solution (>2.4 GBq/(ig indium; Mallinckrodt Medical, 
tten, The Netherlands) via citrate transchelation. The radiochem- 
il purity was determined by instant thinlayer chromatography 
I LC) on Gelman ITLC-SG strips (Gelman Laboratories, Ann Ar- 
T, Mich.) with 0.1 M  citrate (pH = 5) as solvent.
An aliquot of the non-purified 11 'In-DTPA-IgG was incubated 
room temperature for 24 h with a threefold excess of free DTPA 
lated to the amount o f protein-bound DTPA) and then for 1 h 
th a 6000-fold excess of free DTPA. To estimate the amount of 
In liberated by the free DTPA, ITLC was performed on Gelman 
i LC-SG strips with 0.1 M  citrate (pH = 5) as solvent after 0, 1 
nd 24 h incubation with the smaller amount o f DTPA and after 1 
li incubation with the larger quantity of DTPA.
Double-labelled ' 11 In-D TPA-IgG -(l4C). 11'In-labelled IgG was la­
belled with l4C by methylation using l4C-formaldehyde and sodi- 
u»n cyanoborohydride [10]. Briefly: 1.6 ml o f a solution of m In-
IgG [10 MBq 11'In; 2 mg IgG; pH adjusted to 7 with approximate­
ly 0.5 ml 0.15 M  bicarbonate buffer (pH = 8.2)] was added to 0.35 
ml of a solution of 13 MBq l4C-formaldehyde (1.7 GBq/myV/; 
0.064% formaldehyde in water; NEN-Du Pont, Wilmington, Del.) 
in water. Then, 0.7 ml was added of a freshly prepared solution of 
6 mg anhydrous sodium cyanoborohydride (Aldrich Chem. Co. 
Ltd., Gillingham, Dorset, UK) in 1 ml of 0.04 M  phosphate buffer 
(pH = 7). The mixture was incubated for 24 h at room temperature. 
The labelled protein was purified by size exclusion chromatogra­
phy on a Sephadex G-25 containing column (18x1 cm), incubated 
with 0.1 M  acetate buffer (pH = 6). The protein fraction was col­
lected and diluted to 10 ml with phosphate-buffered saline (PBS; 
pH = 7.4). The radiochemical purity was determined by ITLC on 
Gelman ITLC-SG strips with 0.1 M  citrate (pH = 5) as solvent. 
The solution was sterilized by membrane filtration. Based on the 
estimated protein concentration the extent of methylation was cal­
culated.
Aliquots of the purified 1"  In-DTPA-IgG-(14C) were incubated 
at room temperature for 48 h with equal volumes of either PBS or 
rat plasma. After incubation samples were diluted 1:5 with PBS 
and analysed by high performance liquid chromatography (HPLC) 
using a PROTEIN PAK 300 SW column (7.8x300 mm; Millipore- 
Waters, Milford, Mass.) and PBS (pH = 7.4) as mobile phase 
(flow rate 1.0 ml/min). The outflow from the HPLC column was 
monitored by measurement of the optical density at 280 nm 
(OD2h()) and by measurement of the radioactivity. For measure­
ment of the beta and gamma radioactivity 0.25-ml fractions were 
collected. In addition, samples of untreated IgG from the same 
batch as used for labelling were diluted with PBS and analysed by 
HPLC. In this system the void volume is approximately 5 ml, the 
retention volume of IgG and albumin is approximately 7 and 8 ml 
respectively, whereas the retention volume of '"In-D T PA  is ap­
proximately 12 ml.
Single-labelled D TP A -lgG -(N C ).The labelling procedure was sim­
ilar to the procedure for labelling of "  'In-DTPA-IgG-('4C), except 
that no " ' I n  was added. Briefly: 0.5 ml of a solution of DTPA-IgG 
[0.67 mg IgG; pH adjusted to 7 with 0.15 M  bicarbonate buffer 
(pH = 8.2)1 was added to 0.1 ml of a solution of 4 MBq '-^ -fo rm ­
aldehyde (1.7 GBq/mM; 0.064% formaldehyde in water). Then,
0.2 ml was added of a freshly prepared solution of 6 mg sodium 
cyanoborohydride in 1 ml of 0.04 M  phosphate buffer (pH = 7). 
The mixture was incubated for 24 h at room temperature. The la­
belled protein was purified by size exclusion chromatography on a 
Sephadex G-25 containing column (18x1 cm), incubated with 0.1 
M  acetate buffer (pH = 6). The protein fraction was collected, 1 ml 
DTPA-IgG [1.3 mg IgG; pH adjusted to 7 with 0.15 A/ bicarbonate 
buffer (pH = 8.2)] was added, and the mixture was diluted to 10 ml 
with PBS. The radiochemical purity was determined by ITLC on 
Gelman ITLC-SG strips with 0.1 M  citrate (pH = 5) as solvent. 
The solution was sterilized by membrane filtration.
The protein dose per rat was 80 |ig; the l4C dose was 30 kBq 
per rat; the '" I n  dose per rat was either 0 or 0.4 MBq.
Infection m odel and  study design
After ether anaesthesia a calf muscle abscess was induced in 
young, male, randomly bred Wistar rats (weight 200-220 g) with 
approximately 2x10s colony-forming units of S. aureus  in 0.1 ml 
50%:50% suspension of autologous blood and saline. The animals 
were randomly divided into groups of five. Twenty-four hours af­
ter inoculation of S. aureus in the muscle, when swelling of the 
muscle was apparent, the respective radiopharmaceuticals were 
injected in the tail vein.
I-uropean Journal of Nuclear Medicine Vol. 22, No. 3, March 1995
214
To collect tissues, rats were killed with 30 mg intraperitoneally 
injected phénobarbital, followed by cervical dislocation at either
2, 6, 24 or 48 h after injection of the respective radiopharmaceuti­
cal. Both double-labelled 11 lIn-DTPA-lgG-(l4C) and single-la­
belled DTPA-IgG-( 14C) were evaluated in five animals at each 
time point. Samples of bone marrow (taken from the right femur), 
blood and urine were collected. The infected left calf muscle, the 
right calf muscle, the liver, the spleen, one kidney, one lung, the 
duodenum and the right femur were collected and blotted dry. 
Blood, collected in a heparin-containing tube, was centrifuged and 
a plasma sample was taken. Plasma and urine samples taken at 6, 
24 and 48 h were 1:5 diluted with PBS and analysed by HPLC, as 
described above.
The gamma-activity in the tissues and samples was measured 
in a shielded well-type gamma counter. To correct for radioactive 
decay and permit calculation of the uptake of the radiopharmaceu­
ticals in each organ as a fraction of the administered dose, aliquots 
of the respective doses were counted simultaneously. The mea­
sured activity in tissues and samples was expressed as percentage 
of injected dose per gram.
I4C activity was measured by liquid scintillation counting after 
dissolving the tissue samples in 1-ml aliquots of Soluene-350 
(Packard, Meriden, Conn.) at 50°C and decolourizing the tissue 
solutions by incubating overnight with 0.3 ml of 30% hydrogen 
peroxide. Then, 0.2 ml isopropanol was added to stabilize the 
scintillator suspension and 10 ml of Hionic-Fluor (Packard, Meri­
den, Conn.) was added as liquid scintillator. To correct for 
quenching, lOOOOdpm l4C activity was added as an internal stan­
dard. To permit calculation of the uptake of 14C-IgG in each organ 
as a fraction of the administered dose, aliquots of the respective 
doses were counted simultaneously. The results were expressed as 
a percentage of the administered dose per gram of tissue, plasma 
or urine. Care was taken to prevent contribution of 11'In activity to 
the l4C counting results. Therefore the liquid scintillation count­
ing was performed at least 1 month after the 11'In measurements. 
By repeated liquid scintillation counting with 3-day intervals it 
was confirmed that no significant contribution of 11'In activity to 
the l4C countins results was left.
Statistical analysis
All mean values are given ± the standard deviation (SD). Signifi­
cance was set at 0.05 (two-sided). Before carrying out the statisti­
cal testing, all measured values were logtransformed in order to 
obtain homoscedasticity (lognormal distribution). In order to eval­
uate the differences between 11'In and l4C a closed testing proce­
dure 11 11 was carried out in the following way: Student’s t test 
was performed on the samples taken at 48 h after administration. 
Then, only for those tissues which showed a significant difference 
was a / test carried out on the 24-h samples. Again, only if this re­
sult proved significant were the 6-h samples tested, and so on. 
This procedure corresponds to the intuitive idea that one should 
first check the long-term effects, and then -  if these prove signifi­
cant -  proceed to establish from which time onwards these effects 
can be shown. In this way the overall error rate per tissue remains 
at 0.05 (even under partial null hypotheses).
Results
Labelling efficiency, radiochemical purity; 
and stability in vitro
Conjugation of DTPA to IgG resulted in two to three 
DTPA ligands per protein molecule. For 11'In-labelling
of DTPA-IgG the labelling efficiency was 95%. The effi­
ciency of labelling of 1 "In-DTPA-IgG with l4C was ap­
proximately 5%. Approximately 16 amino groups per 
IgG molecule were dimethylated. The average number 
of 14C nuclei per IgG molecule was approximately 2 5 1 
[11a, 11b]. The efficiency of labelling of DTPA-IgG with 
,4C was approximately 15%. For both " 'In-DTPA-IgG- 
( 14C) and DTPA-IgG-(C14), after removing unbound l4C 
and 111 In the radiochemical purity as determined by 
ITLC was better than 99%. Figure 1 presents the HPLC 
profiles for a sample of " 'In-DTPA-IgG-(,4C) incubated 
with PBS buffer at room temperature for 48 h. The OD^80 
profile shows one major peak corresponding to IgG. In 
addition, two or three small peaks are observed with an 
elution volume slightly smaller than that of IgG, possibly 
representing polymers or aggregates (<10%), and another 
small peak with an elution volume similar to that of 
m In-DTPA, representing a low molecular contaminant 
(<2%). The 1HIn and 14C profiles in Fig. 1 completely 
match with the O D 280 profile. The O D 280 profile of un­
treated IgG (not shown) also completely matches with 
the OD280 profile for 1 "In-DTPA-IgG-( '4C). After incu­
bation with plasma for 48 h at room temperature the m In 
and ,4C profiles look very similar to the corresponding 
profiles obtained after incubation with buffer. After incu­
bation of 11'In-DTPA-IgG with free DTPA in threefold 
excess at room temperature the amount of “free” 11'In 
was 4.7% at t -  0, 2.8% at t = 1 h, and 6.3% at t = 24 h. 
After incubation for one additional hour with 6000-fold 
excess of DTPA the amount of “free” 11 'In was 9.3%.
HPLC analysis o f  plasma and urine samples
Figure 2 presents the HPLC profiles for a plasma sample 
taken at 24 h after injection of double-labelled " ' I n -  
DTPA-IgG-(l4C). The O D 280 profile shows various 
peaks and is identical to the O D 280 HPLC profile of a 
plasma sample of an untreated rat (not shown here). The 
,4C plasma profile is very similar to the corresponding 
HPLC profile in Fig. 1. However, the " ' I n  profile shows 
a small shoulder with an elution volume similar to that
1 1. Calculation o f  the average num ber o f  N C nuclei p e r  IgG 
molecule: The average number of disintegrations per time unit in 
radioactive material is linearly related to the number of 
radioactive nuclei present, according to Eq. 1 [ 1 la]:
dN/dt = -X  x/V, (1)
where A = 0.693/7',/2 (2)
For l4C the half-life is 5730 years or 1.81x10" s [ 1 lb]. Thus it fol­
lows from Eq. 2 that A = 3.83x10- '2 per second. Per rat a 14C dose 
of 30 kBq was given with an IgG dose of 80 jag. HPLC analysis 
showed that all 14C activity was bound to IgG. With dN/dt = 30000 
(30 kBq), it follows from Eq. 1 that /V=7.83xl015 l4C nuclei or, 
by dividing by Avogadro’s number (6.02xl023), N  = 1.3x10_s mole 
l4C. 80 pg IgG (estimated molecular weight is 150kDa) is 
5.33x10-'° mole. The average number of l4C nuclei per IgG mole­
cule in our experiment is thus 24.4
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ig. 1. HPLC analysis of double-labelled 11'In -D T P A -IgG -^C ) 
Iter incubation in PBS buffer for 48 h at room temperature. The 
t.pper curve  represents the O D 28() profile. The lower curves  
epresent the activity profiles of 1,1 In and l4C
)f 11'In-transferrin [12]. The 1,1 In activity in this trans- 
helation product is approximately 6% of the plasma ac- 
ivity at 6 h p.i., 9% at 24 h p.i. and 6% at 48 h p.i. Most 
)f the urinary activity of m In had an elution volume on 
JPLC similar to that of m In-DTPA (not shown here). In 
nine HPLC demonstrated various low molecular peaks 
)f l4C activity.
Hssue cl istri but ions
Phe tissue distribution of 11'In-DTPA-IgG-(,4C) is pre- 
ented in Table 1. The tissue distribution of DTPA-IgG- 
l4C) is presented in Table 2.
Figure 3 shows the abscess uptake of both labels in 
louble-labelled 11'In-DTPA-IgG-(l4C) as a function of 
ime. The abscess uptake of indium is constant over 
¡me, whereas the 14C-uptake shows a decreasing trend. 
\ t  48 h after injection the difference between the ab­
scess uptake of indium and of l4C is significantly differ­
ent. In Fig. 4 the quotient of the abscess uptake and the 
plasma concentration of both labels in 11‘In-DTPA-IgG- 
( l4C) is plotted as a function of time after injection. 
From 6 h after injection onwards, the abscess to plasma
0 2 4 6 8 10 12 14 16
Elution volume (ml)
Fig. 2. HPLC analysis of a plasma sample taken at 24 h after 
administration of double-labelled 11 'In-DTPA-IgG-(l4C). The 
upper curve  represents the O D 2iS() profile. The lower cum es  
represent the activity profiles of M1In and l4C
ratio of ,4C is constant, whereas the abscess to plasma 
ratio of indium increases. From 24 h after injection on­
wards, there is a significant difference between the ab­
scess to plasma ratio of 11'In and 14C. The constant ab­
scess to plasma ratio for 14C is in agreement with a ,4C- 
abscess uptake linearly decreasing over time with the 
plasma concentration. By contrast, 11 Un is retained in 
the abscesses despite decreasing plasma concentrations 
of 11'In.
Figure 5 compares the abscess uptake over time of 
the 14C label of double-labelled In-DTPA-IgG-(14C) and 
single-labelled DTPA-IgG-(,4C). Except for the lung at 
48 h after injection, no significant differences are ob­
served between the ,4C tissue distributions of H1In- 
DTPA-IgG-(14C) and DTPA-IgG-(,4C) (cf. Tables 1,2).
At 48 h after administration of double-labelled m In- 
DTPA-IgG-(I4C), the abscess uptake of the m In label is 
significantly higher than the l4C-abscess uptake (cf. Ta­
ble 1). From 24 h after injection onwards, there is a sig­
nificant difference between the 111 In and the 14C concen­
tration in plasma, liver, bone marrow and bone. In plas­
ma from 24 h onwards, the ,4C concentration is higher. 
In liver, bone marrow and bone the 11‘In uptake is high­
er. In spleen, kidney and lung at all time points a signifi-
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Table 1. Biodistribution of '"In-D T PA - 
IgG -(l4C) (percentage of administered dose 
per gram; mean values ± standard devia­
tion; n = 5)
Tissue 2 h 6 h 24 h 48 h
Abscess
" 'I n 1.0 ±0.1 1.0 ±0.1 1.0 ±0.1 1.0 ±0.2*
,4C 1.2 ±0.3 0.8 ±0.3 0.7 ±0.4 0.7 ±0.1*
Muscle
" 'I n . 0.10±0.02 0.11 ±0.02 0 .16±0.03 0 .15±0.04
14C 0 .12±0.03 0.15 ±0.05 0.23±0.03 0 .16±0.09
Plasma
" 'I n 5.9 ±0.5 3.8 ±0.3 1.8 ±0.2* 1.2 ±0.2*
'4C 10 ±1 3.7 ±0.7 3.5 ±0.3* 3.1 ±0.8*
Liver
" 'I n 0.91 ±0.07 0.70±0.08 0.76±0.1 * 1.1 ±0.3*
l4C 1.1 ±0.2 0.6 ±0.2 0.38±0.06* 0.35±0.03*
Spleen
" 'I n 0.8 ±0.1* 0.63±0.03* 0.92±0.05* 1.3 ±0.3*
I4C 1.0 ±0.2* 0.52±0.05* 0.3S±0.06* 0.34±0.07*
Kidney
" 'I n 2.4 ±0.3* 2.4 ±0.2* 2.6 ±0.2* 2.4 ±0.2*
'4C 1.3 ±0.1* 0.69±0.08* 0.62±0.09* 0.53±0.05*
Lunsc
" 'I n 1.1 ±0.1* 0.8 ±0.1* 0.53±0.09* 0.37±0.04*
'4C 1.7 ±0.2* 1.2 ±0.1* 0.9 ±0.2* 0.68±0.07*
Bone marrow
" 'I n 1.5 ±0.3 1.1 ±0.1 0.98±0.05* 0.9 ±0.2*
l4C 1.9 ±0.5 1.1 ±0.1 0.72±0.06* 0.56±0.07*
Bone
" 'I n 0.20±0.04 0.20±0.04 0.24±0.02* 0.19±0.06*
14C 0.25±0.05 0.20±0.04 0 .14±0.02* 0 .10±0.03*
Duodenum
" 'I n 0.36±0.05 0.28±0.04 0.23±0.02 0.20±0.05
l4C 0.57±0.08 0.43±0.09 0.34±0.03 0.25±0.13
Urine
" 'I n 10 ±4 0.6 ±0.3 0.26±0.09 0.21 ±0.05
l4C 4 ±1 1.1 ±0.4 0 .14±0.08 0.4 ±0.5
* Significant difference between 11'In and l4C; paired / test; P<0.05
Table 2. Biodistribution of DTPA-IgG-(,4C) (percentage of 
administered dose per gram; mean values ± standard deviation; 
n = 5)
Tissue 2 h 6 h 24 h 48 h
Abscess 1.1 ±0.1 0.9 ±0.2 0.7 ±0.2 0.61 ±0.05
Muscle 0.08±0.02 0.11 ±0.02 0.18±0.02 0 .19±0.03
Plasma 8 ±1 5.6 ±0.7 3.6 ±0.5 2.5 ±0.2
Liver 0.9 ±0.2 0.56±0.05 0.39±0.06 0.33±0.05
Spleen 0.7 ±0.1 0.6 ±0.2 0.39±0.06 0.34±0.04
Kidney 1.3 ±0.2 0.9 ±0.1 0.5 ±0.1 0.54±0.07
Lung 1.4 ±0.3 1.2 ±0.1 0.8 ±0.1 0.53±0.06
Bone marrow 1.6 ±0.3 0.6 ±0.6 0.8 ±0.1 0.6 ±0.1
Bone 0.19±0.04 0.16±0.06 0.14±0.05 0.11 ±0.02
Duodenum 0.51 ±0.05 0.40±0.04 0.31 ±0.06 0.26±0.03
Urine 3 ±2 0.8 ±0.2 0.21 ±0.03 0 .14±0.03
cant difference is observed between the 11'In and the ,4C 
uptake. In spleen and kidney the 11'In uptake is higher; 
in lung the l4C uptake is higher. In muscle, duodenum 
and urine no significant difference is observed between 
the uptake of the 11'In and the l4C label (cf. Table 1).
The plasma clearance is faster for " ' I n  than for 14C, 
in agreement with the higher retention of " ' I n  in most 
tissues. Moreover, there is a fast excretion of " ' I n  into 
the urine and the urinary excretion of " ' I n  at 2 h  after 
injection seems higher than the urinary excretion of l4C 
at the same time point. The half-life for the second phase 
of the plasma disappearance curve of the l4C label is ap­
proximately 160 h. In liver and spleen the " ' I n  activity 
shows an increase between 6 and 48 h after injection. By 
contrast in these tissues the l4C activity decreases over 
the same time period.
Discussion
In order to provide evidence of the release of  " ' I n  from 
IgG in infectious foci we used so-called double-labelled 
" 'In-DTPA-IgG-( '4C). In this study we introduced an 
external l4C label into IgG by l4C methylation of lysine 
£-amino groups as a substitute for a stable internal label 
like S-35. The preparation of S-35-labelled human IgG 
requires an appropriate cell line and results in the pro­
duction of monoclonal IgG. This does not necessarily










0 6 12 18 24 30 36 42 48
hr p.i.
ig. 3. Abscess uptake over time of both labels of the double- 
ibelled 11 lIn-DTPA-IgG-(14C). Average values for n = 5. The 
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ig. 4. Ratio of abscess activity uptake over plasma concentration 
>f both labels of the double-labelled 11 'In-DTPA-IgG-C'-^C) over 
ime. Average values for n = 5. The vertical bars represent 
tandard deviations
behave exactly like the polyclonal human IgG used in 
‘linical studies. From literature data it is known that re­
ductive alkylation of proteins renders stable products 
without interfering too much with the protein’s proper­
ties [10]. The carbon-nitrogen bond introduced after 
méthylation of lysine £-amino groups is almost as strong 
as a single carbon-carbon bond and is approximately
% I.D./g
40% stronger than the carbon-iodine bond in iodinated 
proteins [13]. Indeed, HPLC analysis of plasma samples 
in this study does not provide evidence of release of the 
l4C label from the 14C-methylated IgG (cf. Fig. 2). 
Moreover, the half-life of the second phase of the plasma 
disappearance curve of the 14C label on IgG (approxi­
mately 1 week) is in agreement with published normal 
values (cf. Table 1) [14].
By reaction with formaldehyde and reduction with 
cyanoborohydride mainly dimethyl derivatives of the ly­
sine residues are formed [10]. Assuming the presence of 
50 lysine residues per IgG molecule, our labelling re­
sults suggest that 30% of the lysine £-amino groups are 
actually methylated. With an average number of 16 di­
methyl amino groups and an average number of 25 ,4C 
nuclei per IgG molecule, all IgG molecules may be as­
sumed to be ,4C labelled. So 11'In-DTPA-IgG-(,4C) is a 
real double-labelled molecule. Methylation of an amino 
group reduces its base strength. A decrease in the protein 
pK of 0.5 unit value as a result of 14C methylation has 
indeed been reported [10]. At least in one case l4C meth­
ylation caused the complete loss of an enzym e’s activity 
[10]. However, in our rat infection model 14C labelling 
of IgG appeared not to interfere with the tissue distribu­
tion of the indium label in the double-labelled m In- 
DTPA-IgG-(,4C) [3]. Moreover, labelling with m In did 
not influence the tissue distribution of 14C-labelled IgG 
(cf. Tables 1, 2).
The results presented in Table 1 and in Figs. 2 -4  
demonstrate a partial dissociation between the M1In and 
the 14C label of double-labelled l l l In-DTPA-IgG-(l4C) 
in abscesses as well as in other tissues like liver and
0
0 6 12 18 24 30 36 42 48
hr p.l.
Fig. 5. Abscess uptake over time of the l4C label of In-DTPA- 
IgG -(l4C) and DTPA-IgG-(l4C). Average values for n = 5. The 
vertical bars represent standard deviations
European Journal of Nuclear Medicine Vol. 22, No. 3, March 1995
218
spleen and in plasma and urine. The abscess to plasma 
ratio of the ,4C-label of double-labelled m In-DTPA- 
IgG -(14C), being constant over time (cf. Fig. 4), dem on­
strates the existence of a linear relationship between the 
l4C concentration in abscesses and the DTPA-lgG-(14C) 
concentration in plasma. This is in agreement with the 
existence of an increased vascular permeability in foci of 
infection and the absence of retention of the l4C-label of 
double-labelled m In-DTPA-IgG-(14C). By contrast, the 
abscess to plasma ratio of the 11 'In-label of 1"  In-DTPA - 
IgG -(l4C) increases over time, demonstrating retention 
of the 11'In-label in the infectious focus despite decreas­
ing plasma concentrations of 1 "In-D TPA -IgG -( '4C). 
This phenomenon provides the basis for the observation 
made in patients of increasing contrast over time be­
tween indium in a site of inflammation and the indium in 
the blood pool.
In plasma the " ' I n / ' 4C ratio, being 1.0 at the time of 
injection, decreases to 0.5 at 24 h and 0.4 at 48 h after 
injection. Since at 48 h the l4C plasma concentration is 
approximately 30% of the initial plasma concentration, 
this means that between 18% and 60% of the plasma 
" ' I n  is released from IgG during the course of the ex- 
periment. Release of " ' I n  from IgG in plasma is also 
supported by the HPLC analysis of a plasma sample at 
24 h p.i. (Fig. 2). Whereas all ,4C activity in plasma 
shows the same profile on HPLC as the injected agent 
[ ' " In -D TPA -IgG -( '4C)] (cf. Figs. 1, 2), there is evidence 
of transchelation of some " ' I n  activity to a macromolec- 
ular species with a lower molecular weight than IgG 
(possibly transferrin). Also, some low molecular " ' I n  
activity is present in plasma at 24 h p.i.
The high level of urinary excretion of " ' I n  at 2 h p.i., 
which seems higher than that of l4C (difference not sig­
nificant), seems to support the suggestion by Davidson 
and co-workers that a part of the " ' I n  is not tightly 
bound to the IgG [15]. In vitro, however, ' "  In-DTPA - 
IgG-( '4C) appears to be rather stable (cf. Fig. 1), since 
incubation in vitro of " 'In-DTPA-IsG with an excess of 
DTPA does not remove more than 5% of the "  'In activi­
ty from the IgG.
There are several possible explanations for the obser­
vation of dissociation of " ' I n  from IgG in inflammatory 
foci. Two of the possible mechanisms of uptake will be 
discussed here.
1. The proteolytic environment in the interstitial fluid 
space of sites of inflammation may enzymatically catab- 
olize labelled IgG and other proteins. Proteolytic en­
zymes in inflammatory foci are released by neutrophils 
and phagocytic cells. Free " 'In -D T PA  is expected to be 
rapidly excreted through the kidneys, unless it is locally 
retained. Endocytosis by inflammation cells with or 
without a receptor might provide an explanation for re­
tention of " ' In -D T P A  in infectious foci. Intracellular re­
tention of " ' I n  after administration of an indium-la­
belled monoclonal antibody has indeed been described 
[16]. Intracellular uptake, however, is not in agreement 
with the observations by Morrel and co-workers, who
found " ' I n  only in the interstitial fluid space of foci of 
infection [2].
Part of the indium in an inflammatory focus may 
transchelate to transferrin, which has a higher affinity for 
indium than protein-conjugated DTPA. Transchelation 
of " ' I n  is supported by the plasma data: HPLC analysis 
reveals that between 6% and 9% of the " ' I n  activity in 
plasma has a slightly larger retention volume than IgG 
and is possibly bound to transferrin (see Fig. 2). Indium 
transferrin is supposed not to interact with transferrin re­
ceptors [17] and since it is soluble under physiological 
conditions, indium transferrin is expected not to be re­
tained in an inflammatory focus. This was confirmed by 
a pilot study with " 'In-transferrin, which demonstrated 
a decreasing trend in the abscess uptake of " ' I n  during 
the first 24 h after injection of " 'In-transferrin  (Claes- 
sens et al., unpublished results). Transchelation of " ' I n  
to transferrin followed by release of indium transferrin 
from the focus of infection might explain the observed 
constant level of " ' I n  uptake in infectious foci (cf. Table 
1), whereas at the given plasma concentrations an in­
creasing "  'In uptake over time should be expected.
2. Hydrolysis and (co)precipitation of indium after re­
lease from " 'In-DTPA-IgG might provide another ex­
planation for dissociation of the two IgG labels and for 
retention of indium in sites of inflammation without the 
need for specific receptors. Recently Sasso and Weiner 
presented results from in vitro experiments showing that 
at slightly decreased pH and in the presence of certain 
mediators an appreciable amount of free "  'In may be re­
leased from '" In-D TPA -IgG  and that under the same 
conditions a smaller quantity of " ' I n  is transchelated to 
lactoferrin [18]. In abscesses the pH is indeed lower than 
in normal tissues, having been reported to be as low as 
6.7 [19] and even lower in diabetic patients [20].
Dissociation of  ' " I n  from double-labelled monoclo­
nal antibodies has been reported previously. Koizumi et 
al. used selenium-75 as an internal label of monoclonal 
antibodies. Indium labelling was performed through 
DTPA. Significant differences between tumour and liver 
uptake of 1 " In  and 75Se were observed [21].
Release of " ' I n  from both IgG and HSA provides an 
explanation for the high ratio between the concentrations 
of " ' In - Ig G  and '" In -H S A  in the interstitial fluid space 
of normal muscle and in plasma, which was reported by 
Juweid and co-workers [22]. A higher protein concentra­
tion in the interstitial fluid space of normal muscle than 
in plasma is very unlikely, since it would cause oedema. 
However, high concentrations of free " ' I n  in the intersti- 
tium of normal muscle do not interfere with normal 
physiological conditions.
Since tumours often show inflammatory reactions and 
increased vascular permeability, release of indium from 
a ' "In-DTPA-monoclonal antibody and local retention 
might also contribute to the uptake of " ' I n  in tumours. 
In cases where positive localization of indium has been 
reported without the local presence of specific receptors 
for the antibody involved, release of " ‘In from the la­
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belled antibody may provide an adequate explanation for 
non-specific accumulation of m In in tumours [23].
In conclusion: Indium is released from indium- 
DTPA-IgG and retained free from IgG in infectious foci. 
Several mechanisms may explain this observation. Addi- 
ional experimental work by our group has provided in- 
Jications of retention of free Ini 11-DTPA in sites of in­
fection [24]. Part of the indium seems to be transchelat­
ed to transferrin and may thus leave the infection. How 
MIn-DTPA is retained after dissociation from IgG is not 
yet known. Further studies are necessary to elucidate the 
letails of the mechanism of uptake of indium in sites of 
inflammation after administration of 11'In-DTPA-IgG.
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